Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT04095195
Recruiting Observational

Registry of Subjects at Risk of Pancreatic Cancer

NCT04095195 · tracked via the Priya Life Science Italy tracker
Sponsor
Associazione Italiana per lo Studio del Pancreas
Phase
Observational
Started
2019-08-20
Last updated
2023-01-13

Condition(s) studied

Familial Pancreatic CancerBRCA1 MutationBRCA2 MutationLynch SyndromeFAMMM - Familial Atypical Mole Malignant Melanoma SyndromeHereditary PancreatitisPeutz-Jeghers Syndrome

Investigational drug(s) / intervention(s)

MRCPEndoultrasonography

MRCP: Subjects fulfilling the "radiological follow-up criteria" will be submitted to MRCP or EUS according to the pancreatologist's prescription

Endoultrasonography: Subjects fulfilling the "radiological follow-up criteria" will be submitted to MRCP or EUS according to the pancreatologist's prescription

Study summary

IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria to enter the registry: * individuals with at least two relatives suffering from pancreatic cancer, with at least 1 first-degree and until the third-degree * subjects with known genetic mutation of BRCA2, BRCA1, p16, PALB2 with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer * subjects suffering from FAMMM Syndrome * subjects suffering from Peutz-Jeghers Syndrome * subjects suffering from PRSS-1- or CFTR- or SPINK-1- related pancreatitis * subjects suffering from Lynch syndrome with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer Inclusion criteria to join the "radiologic follow-up": * 45 years or 10 years younger than the youngest index case of pancreatic cancer in the family for familial cases * 40 years or 5 years younger than the youngest index case of pancreatic cancer for subjects suffering from hereditary/genetic pancreatitis, Lynch syndrome, or carrying a known BRCA 1/2, PALB2, p16 genetic mutation with familiarity for pancreatic cancer * 30 years for subjects suffering from FAMMM, Peutz-Jeghers syndrome Exclusion Criteria: \- pregnancy

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Istituto Clinico Humanitas Rozzano Milan Recruiting
Ospedale Pederzoli Peschiera del Garda Verona Recruiting
San Raffele Vita Salute University Hospital Milan Italy Recruiting
Chirurgia Generale e del Pancreas Verona Italy Recruiting

More Associazione Italiana per lo Studio del Pancreas trials in Italy

Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL) Active, not recruiting
Italian Registry of Minimally Invasive Pancreatic Surgery Recruiting
Familial Pancreatic Cancer PROPHilation Program in Italy Recruiting
Italian Registry Chronic Pancreatitis Recruiting

Other trials for the same condition

Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome Starting soon
EC_ItaLynch: Mainstreaming the Diagnosis of Lynch Syndrome Starting soon
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System Recruiting
BRCA Mutation Carriers' Platform a Multicenter Study Recruiting
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04095195 on ClinicalTrials.gov ↗ ← All trials in Italy